Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $25.2200 (-2.55%) ($24.8500 - $26.4000) on Tue. Sep. 15, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.01% (three month average) | RSI | 59 | Latest Price | $25.2200(-2.55%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.1% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -2.005% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-18%) DRIV(-5%) TBT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.005% (StdDev 4.01%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $25.34(-0.47%) | 10 Day Moving Average | $25.3(-0.32%) | 20 Day Moving Average | $24.6(2.52%) | To recent high | -7.4% | To recent low | 39.4% | Market Cap | $3.194b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |